Douglas J. Sheffler
Affiliations: | Vanderbilt University, Nashville, TN |
Google:
"Douglas Sheffler"Mean distance: 14.7 (cluster 6) | S | N | B | C | P |
Parents
Sign in to add mentor| Bryan L. Roth | grad student | 1998-2006 | Case Western | |
| (The regulation of G protein-coupled receptor (GPCR) signal transduction by p90 ribosomal S6 kinase 2 (RSK2).) | ||||
| Jeffrey P. Conn | post-doc | Vanderbilt | ||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Barnes SA, Sheffler DJ, Semenova S, et al. (2018) Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy. Biological Psychiatry |
| Walker AG, Sheffler DJ, Lewis AS, et al. (2017) Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP, Long-Term Potentiation, and Disrupts Memory Reconsolidation. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology |
| Smith E, Chase P, Niswender CM, et al. (2015) Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4). Journal of Biomolecular Screening |
| Dhanya RP, Sheffler DJ, Dahl R, et al. (2014) Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. Journal of Medicinal Chemistry. 57: 4154-72 |
| Sheffler DJ, Nedelovych MT, Williams R, et al. (2014) Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: development of a [3.3.0]-based series and other piperidine bioisosteres. Bioorganic & Medicinal Chemistry Letters. 24: 1062-6 |
| Jones CK, Sheffler DJ, Williams R, et al. (2014) Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead. Bioorganic & Medicinal Chemistry Letters. 24: 1067-70 |
| Poslusney MS, Melancon BJ, Gentry PR, et al. (2013) Spirocyclic replacements for the isatin in the highly selective, muscarinic M1 PAM ML137: the continued optimization of an MLPCN probe molecule. Bioorganic & Medicinal Chemistry Letters. 23: 1860-4 |
| Melancon BJ, Poslusney MS, Gentry PR, et al. (2013) Isatin replacements applied to the highly selective, muscarinic M1 PAM ML137: continued optimization of an MLPCN probe molecule. Bioorganic & Medicinal Chemistry Letters. 23: 412-6 |
| Sheffler DJ, Sevel C, Le U, et al. (2013) Further exploration of Mâ‚ allosteric agonists: subtle structural changes abolish Mâ‚ allosteric agonism and result in pan-mAChR orthosteric antagonism. Bioorganic & Medicinal Chemistry Letters. 23: 223-7 |
| Le U, Melancon BJ, Bridges TM, et al. (2013) Discovery of a selective Mâ‚„ positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia. Bioorganic & Medicinal Chemistry Letters. 23: 346-50 |